2012 Economic Outlook - Report Highlights Akorn, Inc. and Ironwood Pharmaceuticals, Inc.

HONG KONG -- (Marketwire) -- 02/27/12 -- Today, www.BrightonMarkets.com announced new reports highlighting Akorn, Inc. (NASDAQ: AKRX) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD). Gain market insight with full analysis and research downloads available at www.BrightonMarkets.com/index.php?coa=AKRX&cob=IRWD.

Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experience in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.

Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.

Brighton Markets is releasing new coverage on Akorn, Inc. for its current position within the healthcare industry. Akorn, Inc. manufactures and markets a range of diagnostic and therapeutic ophthalmic pharmaceuticals, as well as niche hospital drugs and injectable pharmaceuticals. In addition, the Company has marketed and distributed vaccines purchased from outside sources. The Company operates in three segments: ophthalmic; hospital drugs and injectables, and contract services. The full research report on Akorn, Inc. (NASDAQ: AKRX) is available here: www.BrightonMarkets.com/index.php?coa=AKRX.

Brighton Markets has released research on Ironwood Pharmaceuticals, Inc. for its changing role within the healthcare industry. Ironwood Pharmaceuticals, Inc. is a pharmaceutical company that discovers and develops medicines. As of December 31, 2010, Linaclotide, the Company's guanylate cyclase type-C (GC-C) agonist, was developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C) or chronic constipation (CC). The full research report on Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) is available here: www.BrightonMarkets.com/index.php?cob=IRWD.

About Brighton Markets
Brighton Markets was founded on the guiding principle of providing highly relevant, meaningful, and actionable information direct to investors. Across the investment spectrum, Brighton Markets shines light on today's events.


Jean Barnes
email Email Contact

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here